SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MacroGenics Reports Lorigerlimab Response in Phase 2 Tumor Study

The study evaluated lorigerlimab in clear-cell gynecologic tumors.

MGNX

Related stories